Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Justice Department Opens Investigation Into Fluvirin

This article was originally published in The Pink Sheet Daily

Executive Summary

Chiron is responding to a grand jury subpoena from the New York City U.S. Attorney's Office regarding Fluvirin

You may also be interested in...



Chiron Issues Fourth Quarter, Full-Year Earnings Restatement

The restatement is the result of improper revenue recognition of traveler vaccines in the second quarter and later periods, Chiron says. The company also reports lower flu vaccine sales as part of the restatement.

Chiron Issues Fourth Quarter, Full-Year Earnings Restatement

The restatement is the result of improper revenue recognition of traveler vaccines in the second quarter and later periods, Chiron says. The company also reports lower flu vaccine sales as part of the restatement.

CDC, Distributors Could Sue Chiron For Failing To Supply Fluvirin

Centers for Disease Control & Prevention issues a notice asking why Chiron should not be held in default for failing to supply Fluvirin to the government, the company says in an SEC filing. Fluvirin distributors have also suggested that they should be compensated under their contracts for the 2004-2005 season.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel